SCHEMBL7607153

SCHEMBL7607153

CNC(=O)C(CC(=O)OCc1ccccc1)n1ccc(-c2ccc(-c3ccncc3)cc2)c1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 1/20 0.42
ALDH1A1 P00352 1/20 0.41
HPGD P15428 1/20 0.41
NPSR1 Q6W5P4 1/20 0.41
HRH4 Q9H3N8 1/20 0.40
CYP2D6 P10635 1/20 0.38
CYP2C9 P11712 1/20 0.38
GRIN2B Q13224 1/20 0.38
HDAC8 Q9BY41 2/20 0.38
AAK1 Q2M2I8 1/20 0.38
ROCK2 O75116 6/20 0.38
ROCK1 Q13464 5/20 0.38
CYP26A1 O43174 1/20 0.38
RPS6KA5 O75582 1/20 0.37
MAP4K4 O95819 1/20 0.37
PRKCG P05129 1/20 0.37
PRKACA P17612 1/20 0.37
RPS6KB1 P23443 1/20 0.37
MAPK1 P28482 1/20 0.37
AKT1 P31749 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7457294 1.00 POLB (0.42) POLBALDH1A1HPGDNPSR1HRH4
SCHEMBL7609006 0.90 MMP3 (0.42) ALDH1A1HPGDNPSR1AAK1MMP9
SCHEMBL7609014 0.90 MMP3 (0.42) ALDH1A1HPGDNPSR1AAK1MMP9
SCHEMBL7607176 0.89 MMP3 (0.42) ALDH1A1HPGDNPSR1MMP9MMP1
SCHEMBL7450217 0.89 MMP3 (0.42) ALDH1A1HPGDNPSR1MMP9MMP1
SCHEMBL7449992 0.89 ALDH1A1 (0.45) POLBALDH1A1HPGDNPSR1HRH4
Hydrochloric Acid SCHEMBL7595280 0.88 ALDH1A1 (0.44) POLBALDH1A1HPGDNPSR1HRH4
Hydrochloric Acid SCHEMBL7455276 0.88 ALDH1A1 (0.44) POLBALDH1A1HPGDNPSR1HRH4
SCHEMBL7447895 0.85 MMP2 (0.49) POLBALDH1A1HPGDNPSR1HRH4
SCHEMBL7604089 0.85 MMP2 (0.49) POLBALDH1A1HPGDNPSR1HRH4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6495699-B2 ANTIARTHRITIC AGENTS; OSTEOPOROSIS AGOURON PHARMACEUTICALS INC. 2002-12-17 US disclosed
US-20020019429-A1 Metalloproteinase inhibitors, pharmaceutical compositions containing them, and their use BENDER STEVEN L (US) 2002-02-14 US disclosed
US-6306892-B1 ENZYME INHIBITORS HETEROCYCLIC AMIDES AGOURON PHARMACEUTICALS, INC. 2001-10-23 US disclosed
US-6174915-B1 FOR TREATING MAMMALIAN DISEASE CONDITION MEDIATED BY METALLOPROTEINASE ACTIVITY AGOURON PHARMACEUTICALS, INC. 2001-01-16 US disclosed
US-6008243-A AN ENZYME INHIBITOR FOR PREVENTING THE DEGRADATION AND REMODELING OF CONNECTIVE TISSUES AGOURON PHARMACEUTICALS, INC. (US) 1999-12-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020019429-A1 Metalloproteinase inhibitors, pharmaceutical compositions containing them, and their use MMP9, MMP2, MMP3 POLB 2433/4885ALDH1A1 733/4885HPGD 245/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.